Mark H. Mirochnick, MD
Professor
Boston University School of Medicine
Dept of Pediatrics
Neonatology Section

MD, University of Vermont College of Medicine



Section Director
Boston University School of Medicine
Pediatrics
Neonatology Section

Active Staff Privileges
Boston Medical Center
Pediatrics




A 48 Week, Phase II, Open-Label, Multi-Cohort, Multicenter Study to Evaluate the Safety , Tolerability, Pharmacokinetics, and Antiviral Activity of GW433908/Ritonavir QD when Administered to HIV-1 Infected, Antiretrovitral Naive and Experienced, Pediatric
07/01/2002 - 06/30/2006 (PI)
GlaxoSmithKline, Inc.

Open-Label Multicenter Multiple Dose Phase III Study of the Population Pharmacokinetics of IV Synecid 7.5 mg/kg q8h in &5 Pediatric Patients
11/01/2001 - 10/31/2003 (PI)
Aventis Pharmaceuticals Inc

Investigation of CD11b Expression in Neonates Using New Laser Scanning Cytometer Technology
10/19/1999 - 09/30/2000 (PI)
CompuCyte Corporation


IMPAACT 2007 - Phase I Safety and Pharmacokeneticks of Marviorc in HIV 1 Exposed Infants at Risk …
07/01/2016 - 12/31/2017 (PI)
Johns Hopkins University Phivco UK II Ltd.

LOC-IMPAACT Leadership Group: Mirochnik
01/01/2014 - 11/30/2017 (PI)
Johns Hopkins University NIH-NIAID

Plugging Hair ARV Levels as Adherence Biomarkers into HIV Prevention Trials
12/01/2012 - 11/30/2016 (PI)
Univ of California, San Francisco NIH-NIAID

IMPAACT: HIV Treatment SC VC
06/01/2012 - 12/31/2014 (PI)
Johns Hopkins University NIH-NIAID

IMPAACT: Network Executive Committee (NEC)
06/01/2012 - 12/31/2013 (PI)
Johns Hopkins University NIH-NIAID

IMPAACT Group Leadership
07/01/2006 - 06/30/2013 (PI)
Social & Scientific Systems Inc. NIH-NIAID

Pharmacokinetic Study of Praziquantel During Pregnancy
04/01/2009 - 03/31/2013 (PI)
Rhode Island Hospital NIH-NIAID

IMPAACT Leadership: International Maternal Pediatric Adolescent AIDS Clinical Trials Group (IMPAACT)
06/01/2011 - 05/31/2012 (PI)
Social & Scientific Systems Inc. NIH-NIAID

Congenital Transmission of Lineages I and II of Trypanasoma Cruzi
09/08/2011 - 02/29/2012 (PI)
Tulane Univ Health Sciences Center NIH-NIA

Phase III Randomized Trial of the Safety and Efficency
11/01/2003 - 11/30/2010 (PI)
WESTAT NIH-NICHD

Showing 10 of 14 results. Show All Results


Yr Title Project-Sub Proj Pubs
2008 Safety Pharmacokinetics &Efficacy of Artemether &Lumefantrine in Pregnant Women 1R34AI076610-01
2007 ANTIRETROVIRAL DRUGS DURING PREGNANCY, SUBSTUDY OF PACTG P1025 2M01RR000533-39-8139 429
2007 PERINATAL CORE PROTOCOL FOR HIV INFECTED WOMEN (PACTG P1025, VERSION 20) 2M01RR000533-39-8144 429
2007 PHARMACOKINETICS OF ANTIRETROVIRAL DRUGS IN PREGNANT HIV INFECTED WOMEN 2M01RR000533-39-8160 429
2006 ANTIRETROVIRAL DRUGS DURING PREGNANCY, HIV INFECTED WOMEN (SUB OF PACTG P1025) 5M01RR000533-38-5584 429
2006 PERINATAL CORE PROTOCOL FOR HIV INFECTED WOMEN (PACTG P1025, VERSION 20) 5M01RR000533-38-5591 429
2006 Antiretroviral Pharmacology/Lactating Mother/Infants 5R21HD051470-02 1
2005 Antiretroviral Pharmacology/Lactating Mother/Infants 1R21HD051470-01 1
2005 ANTIRETROVIRAL DRUGS DURING PREGNANCY IN HIV POSITIVE FEMALES 5M01RR000533-37-5424 429
2005 PERINATAL CORE PROTOCOL IN HIV INFECTED WOMEN (PACTG P1025, VERSION 20) 5M01RR000533-37-444 429
Showing 10 of 22 results. Show All Results
Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.

  1. Osorio LE, Boechat MI, Mirochnick M, Kumwenda N, Kreitchmann R, Emel L, Pinto J, Joao E, Santos B, Swenson M, George K, Sato P, Mofenson L, Nielsen-Saines K. Bone Age and Mineral Density Assessments Using Plain Roentgenograms in Tenofovir-exposed Infants in Malawi and Brazil Enrolled in HIV Prevention Trials Network 057. Pediatr Infect Dis J. 2017 Feb; 36(2):184-188. PMID: 27798550; DOI: 10.1097/INF.0000000000001386;.
  2. Mulligan N, Schalkwijk S, Best BM, Colbers A, Wang J, Capparelli EV, Moltó J, Stek AM, Taylor G, Smith E, Hidalgo Tenorio C, Chakhtoura N, van Kasteren M, Fletcher CV, Mirochnick M, Burger D. Etravirine Pharmacokinetics in HIV-Infected Pregnant Women. Front Pharmacol. 2016; 7:239. PMID: 27540363; DOI: 10.3389/fphar.2016.00239;.
  3. Tran AH, Best BM, Stek A, Wang J, Capparelli EV, Burchett SK, Kreitchmann R, Rungruengthanakit K, George K, Cressey TR, Chakhtoura N, Smith E, Shapiro DE, Mirochnick M. Pharmacokinetics of Rilpivirine in HIV-Infected Pregnant Women. J Acquir Immune Defic Syndr. 2016 Jul 01; 72(3):289-96. PMID: 26918544; PMCID: PMC4911231; DOI: 10.1097/QAI.0000000000000968;.
  4. Gupta A, Mathad JS, Abdel-Rahman SM, Albano JD, Botgros R, Brown V, Browning RS, Dawson L, Dooley KE, Gnanashanmugam D, Grinsztejn B, Hernandez-Diaz S, Jean-Philippe P, Kim P, Lyerly AD, Mirochnick M, Mofenson LM, Montepiedra G, Piper J, Sahin L, Savic R, Smith B, Spiegel H, Swaminathan S, Watts DH, White A. Toward Earlier Inclusion of Pregnant and Postpartum Women in Tuberculosis Drug Trials: Consensus Statements From an International Expert Panel. Clin Infect Dis. 2016 Mar 15; 62(6):761-9. PMID: 26658057; PMCID: PMC4772846; DOI: 10.1093/cid/civ991;.
  5. Cotton MF, Holgate S, Nelson A, Rabie H, Wedderburn C, Mirochnick M. The last and first frontier--emerging challenges for HIV treatment and prevention in the first week of life with emphasis on premature and low birth weight infants. J Int AIDS Soc. 2015; 18(Suppl 6):20271. PMID: 26639118; PMCID: PMC4670832; DOI: 10.7448/IAS.18.7.20271;.
  6. Stek A, Best BM, Wang J, Capparelli EV, Burchett SK, Kreitchmann R, Rungruengthanakit K, Cressey TR, Mofenson LM, Smith E, Shapiro D, Mirochnick M. Pharmacokinetics of Once Versus Twice Daily Darunavir in Pregnant HIV-Infected Women. J Acquir Immune Defic Syndr. 2015 Sep 1; 70(1):33-41. PMID: 25950206; PMCID: PMC4579345; DOI: 10.1097/QAI.0000000000000668;.
  7. Colbers A, Best B, Schalkwijk S, Wang J, Stek A, Hidalgo Tenorio C, Hawkins D, Taylor G, Kreitchmann R, Burchett S, Haberl A, Kabeya K, van Kasteren M, Smith E, Capparelli E, Burger D, Mirochnick M. Maraviroc Pharmacokinetics in HIV-1-Infected Pregnant Women. Clin Infect Dis. 2015 Nov 15; 61(10):1582-9. PMID: 26202768; PMCID: PMC4614410; DOI: 10.1093/cid/civ587;.
  8. Best BM, Burchett S, Li H, Stek A, Hu C, Wang J, Hawkins E, Byroads M, Watts DH, Smith E, Fletcher CV, Capparelli EV, Mirochnick M. Pharmacokinetics of tenofovir during pregnancy and postpartum. HIV Med. 2015 Sep; 16(8):502-11. PMID: 25959631; PMCID: PMC4862736; DOI: 10.1111/hiv.12252;.
  9. Sheffield JS, Siegel D, Mirochnick M, Heine RP, Nguyen C, Bergman KL, Savic RM, Long J, Dooley KE, Nesin M. Designing drug trials: considerations for pregnant women. Clin Infect Dis. 2014 Dec 15; 59 Suppl 7:S437-44. PMID: 25425722; PMCID: PMC4303056; DOI: 10.1093/cid/ciu709;.
  10. Watts DH, Stek A, Best BM, Wang J, Capparelli EV, Cressey TR, Aweeka F, Lizak P, Kreitchmann R, Burchett SK, Shapiro DE, Hawkins E, Smith E, Mirochnick M. Raltegravir pharmacokinetics during pregnancy. J Acquir Immune Defic Syndr. 2014 Dec 1; 67(4):375-81. PMID: 25162818; PMCID: PMC4213295; DOI: 10.1097/QAI.0000000000000318;.
Showing 10 of 94 results. Show More

This graph shows the total number of publications by year, by first, middle/unknown, or last author.

Bar chart showing 94 publications over 29 distinct years, with a maximum of 9 publications in 2011

YearPublications
19863
19881
19901
19911
19933
19943
19951
19962
19971
19983
19997
20004
20013
20023
20033
20041
20054
20063
20072
20086
20093
20103
20119
20125
20134
20147
20155
20162
20171
Contact for Mentoring:


771 Albany St
Boston MA 02118
Google Map


Mirochnick's Networks
Click the "See All" links for more information and interactive visualizations
Concepts
_
Co-Authors
_
Similar People
_
Same Department